title: Preparation and characterization of dextran nanobubbles for oxygen delivery.
abstract: Dextran nanobubbles were prepared with a dextran shell and a perfluoropentan core in which oxygen was stored. To increase the stability polyvinylpirrolidone was also added to the formulation as stabilizing agent. Rhodamine B was used as fluorescent marker to obtain fluorescent nanobubbles. The nanobubble formulations showed sizes of about 500nm, a negative surface charge and a good capacity of loading oxygen, no hemolytic activity or toxic effect on cell lines. The fluorescent labelled nanobubbles could be internalized in Vero cells. Oxygen-filled nanobubbles were able to release oxygen in different hypoxic solutions at different time after their preparation in in vitro experiments. The oxygen release kinetics could be enhanced after nanobubble insonation with ultrasound at 2.5MHz. The oxygen-filled nanobubble formulations might be proposed for therapeutic applications in various diseases.
authors.affiliation: Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino - Via Pietro Giuria 9 - 10125, Torino, Italy. roberta.cavalli@unito.it
authors.forename: R
authors.initials: R
authors.lastname: Cavalli
authors.forename: A
authors.initials: A
authors.lastname: Bisazza
authors.forename: P
authors.initials: P
authors.lastname: Giustetto
authors.forename: A
authors.initials: A
authors.lastname: Civra
authors.forename: D
authors.initials: D
authors.lastname: Lembo
authors.forename: G
authors.initials: G
authors.lastname: Trotta
authors.forename: C
authors.initials: C
authors.lastname: Guiot
authors.forename: M
authors.initials: M
authors.lastname: Trotta
mesh_terms: D000818:Animals; D015687:Cell Hypoxia; D002470:Cell Survival / Q000187:drug effects; D002522:Chlorocebus aethiops; D003911:Dextrans / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D004705:Endocytosis; D005079:Excipients / Q000737:chemistry; D005466:Fluorocarbons / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D053878:Hemolytic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000860:Hypoxia / Q000628:therapy; D045423:Microbubbles / Q000009:adverse effects; D049329:Nanostructures / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D009391:Nephelometry and Turbidimetry; D010100:Oxygen / Q000008:administration & dosage* / Q000032:analysis; D010949:Plasma / Q000737:chemistry; D011205:Povidone / Q000737:chemistry; D051381:Rats; D012965:Sodium Chloride / Q000737:chemistry; D013010:Sonication; D013499:Surface Properties; D013997:Time Factors; D014709:Vero Cells; D010420:Pentanes
chemical_list: D003911:Dextrans; D005079:Excipients; D005466:Fluorocarbons; D053878:Hemolytic Agents; D010100:Oxygen; D011205:Povidone; D012965:Sodium Chloride; C008806:perfluoropentane; D010420:Pentanes